Yutaka Okano

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Sarcoidosis-like reaction associated with tocilizumab in a patient with giant cell arteritis: a case based review.

Sarcoidosis-like reaction associated with tocilizumab in a patient with giant cell arteritis: a case based review.

Journal: Rheumatology international

Published: April 08, 2026

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

Journal: RMD open

Published: October 15, 2025

Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.

Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.

Journal: Annals of the rheumatic diseases

Published: July 01, 2024

Atypical Cogan's Syndrome with Large-vessel Vasculitis Successfully Treated with Tocilizumab.

Atypical Cogan's Syndrome with Large-vessel Vasculitis Successfully Treated with Tocilizumab.

Journal: Internal medicine (Tokyo, Japan)

Published: April 09, 2023

Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab.

Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab.

Journal: Modern rheumatology case reports

Published: March 17, 2023

Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.

Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.

Journal: The Lancet. Rheumatology

Published: December 05, 2022

Aseptic meningitis as an initial manifestation of primary Sjögren's syndrome.

Aseptic meningitis as an initial manifestation of primary Sjögren's syndrome.

Journal: Modern rheumatology case reports

Published: September 28, 2022

Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study.

Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study.

Journal: Scientific reports

Published: July 26, 2022

Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.

Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.

Journal: Rheumatology international

Published: July 23, 2022

Allergic disorders and their risk factors in primary Sjögren's syndrome.

Allergic disorders and their risk factors in primary Sjögren's syndrome.

Journal: The World Allergy Organization journal

Published: June 28, 2022

Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.

Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.

Journal: Modern rheumatology case reports

Published: April 21, 2022

Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins.

Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins.

Journal: Immunological medicine

Published: April 07, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026